publication date: Dec. 12, 2014

NCI’s Lowy and Schiller Honored with National Medal


NCI’s Douglas Lowy and John Schiller were honored by President Barack Obama with a National Medal of Technology and Innovation, the nation’s highest honor for technological achievement, for their work in developing a vaccine for human papilloma virus.

Lowy, deputy director of NCI, and Schiller, of the Laboratory of Cellular Oncology in the NCI Center for Cancer Research, received their awards at a White House Ceremony Nov. 20.

“Douglas Lowy and John Schiller have collaborated for nearly 30 years,” said Obama.

“When they presented their research to drug companies, many told them that while their data looked good, a vaccine against this sexually transmitted disease just wasn’t going to work. But with the help of NIH research funding, they helped create one of the most successful preventive treatments in decades, potentially saving the lives of millions of young women and girls.”

Lowy’s and Schiller’s research directly led to vaccines that protect against infection with the HPV types that cause most cervical cancers in women and anal and oral cancers in both sexes, as well as HPV types that cause genital warts in both sexes, according to NCI.

During the joint meeting of the NCI Board of Scientific Advisors and the National Cancer Advisory Board Dec. 2, NCI Director Harold Varmus again honored Lowy and Schiller, and said that the statements made by the president are “very helpful to all of us—from the point of view of enhancing the reputation of the NIH and the NCI, to making a better case for the vaccine.”

Varmus also presented a video produced by the National Science and Technology … Continue reading 40-46 NCI’s Lowy and Schiller Honored with National Medal

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.